January 13, 2025 02:30 AM EST
R&D

Bay­er’s Blue­Rock now plans to bring Parkin­son’s cell ther­a­py straight to Phase 3 tri­al

Lei Lei Wu

News Reporter

Bay­er’s ex­per­i­men­tal Parkin­son’s dis­ease ther­a­py made from stem cells will soon en­ter late-stage stud­ies, mark­ing a key test for re­gen­er­a­tive med­i­cine in neu­ro­log­ic con­di­tions. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug

J&J looks at po­ten­tial bid for In­tra-Cel­lu­lar — re­port

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic

A service from the Financial Times